SOURCE: Academy of Managed Care Pharmacy

June 06, 2005 12:48 ET

E-prescribing System Had No Effect on Formulary Compliance or Generic Drug Utilization Versus Traditional Prescribing; Plus, Differences Found in the Relative Cost-Effectiveness of Triptan Drugs

ALEXANDRIA, VA -- (MARKET WIRE) -- June 6, 2005 -- The June 2005 issue of the Journal of Managed Care Pharmacy (JMCP) is now available in print and online. Featured articles include:

E-prescribing System Had No Effect on Formulary Compliance or Generic Drug Utilization Ratio...

Analysis of 110,975 administrative pharmacy claims for 12 months revealed no difference between 95 predominant e-prescribing physicians and 95 traditional prescribers in two key measures of performance. Drug formulary compliance was 83.2% for predominant e-prescribers versus 82.8% for traditional prescribers (P = 0.32) and 82.0% for the overall prescriber population. There was also no difference in the ratio of generic drug use: 37.3% for predominant e-prescribers versus 36.9% for traditional prescribers (P = 0.18). An accompanying editorial asks the question, "Why e-prescribe?" in the context of an article in the May 2005 issue of JMCP. That article reported how e-prescribing combined with clinical decision support achieved significant drug cost savings and reduction in certain high-cost drugs in 8 therapeutic classes that had been targeted for therapeutic substitution by the e-prescribing system.

Cost-effectiveness Analysis Found Two-fold Difference Between the Most Cost-Effective Triptan and the Least Cost-Effective Triptan ...

A pharmacoeconomic analysis based upon a previously published meta-analysis of clinical trials of 6 triptan (Imitrex-like) drugs in 9 dosage strengths found that eletriptan 40 mg required the lowest number of patients (361) per 100 needed to treat (NNT) to achieve a 2-hour postdose pain response, sustained through 24 hours, compared with 597 patients NNT with rizatriptan 5 mg to achieve this outcome in 100 patients. An alternate measure of doses needed to treat (DNT) found 388 doses necessary for eletriptan 40 mg to achieve the desired pain response in 100 patients compared with 662 doses DNT for rizatriptan 5 mg. The cost to successfully treat one patient-episode ranged from $56.30 for eletriptan 40 mg to $111.36 for naratriptan 2.5 mg. An accompanying editorial addresses the subject of meta-analyses pertaining to triptan clinical trials and points out that the meta-analysis relied upon for this cost-effectiveness analysis concluded that eletriptan 80 mg had the highest likelihood of consistent success in relief of migraine episodes, a dose that is not available in the United States.

The Journal of Managed Care Pharmacy is published nine times per year and is a benefit of membership in the Academy of Managed Care Pharmacy. A peer-reviewed publication of original research for pharmacy practitioners and health care providers, JMCP is approved by the National Library of Medicine and indexed in MEDLINE/PubMed. The current edition is available at: http://www.amcp.org/amcp.ark?c=jmcp&sc=articles&year=2005&volume=11&issue=5

Questions about the publication may be directed to Editor-in-Chief Frederic R. Curtiss, PhD, RPh, CEBS, at fcurtiss@amcp.org.

The Academy of Managed Care Pharmacy's mission is to empower its members to serve society by using sound medication management principles and strategies to achieve positive patient outcomes. AMCP has more than 4,800 members nationally who provide comprehensive coverage and services to the more than 200 million Americans served by managed care. More news and information about AMCP can be obtained on their website, www.amcp.org.

Contact Information